November 29, 2016 / 8:25 AM / a year ago

Actelion shares plunge on report it eyes 'complicated' J&J deal

ZURICH (Reuters) - Shares in Swiss biotech company Actelion ATLN.S plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a “complicated deal” to link with U.S. healthcare giant Johnson & Johnson (JNJ.N).

Actelion shares fell more than 8 percent in early trading, after having risen sharply over the last four days to value the company at about $20 billion amid takeover speculation.

    Johnson & Johnson approached Actelion Chief Executive Jean-Paul Clozel expecting him to reject a takeover, so it instead has focused on another proposal to take a major stake in the Swiss company while leaving it independent, the Financial Times reported late on Monday.

    Actelion declined to comment on the FT report. A Johnson & Johnson spokesman also declined comment.

    Reporting by John Miller, editing by Michael Shields

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below